CN107980043B - 多肽用于制备作用于免疫信号转导和/或影响肠屏障功能和/或调节代谢状态的药物 - Google Patents

多肽用于制备作用于免疫信号转导和/或影响肠屏障功能和/或调节代谢状态的药物 Download PDF

Info

Publication number
CN107980043B
CN107980043B CN201680026195.4A CN201680026195A CN107980043B CN 107980043 B CN107980043 B CN 107980043B CN 201680026195 A CN201680026195 A CN 201680026195A CN 107980043 B CN107980043 B CN 107980043B
Authority
CN
China
Prior art keywords
polypeptide
cholesterol
nucleic acid
mammal
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680026195.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN107980043A (zh
Inventor
克莱拉·贝尔泽
威廉·迈因德特·德沃斯
帕特里斯·丹尼尔·卡尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catholic University Of Luwan
Wageningen Universiteit
Original Assignee
Catholic University Of Luwan
Wageningen Universiteit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catholic University Of Luwan, Wageningen Universiteit filed Critical Catholic University Of Luwan
Publication of CN107980043A publication Critical patent/CN107980043A/zh
Application granted granted Critical
Publication of CN107980043B publication Critical patent/CN107980043B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201680026195.4A 2015-05-06 2016-05-04 多肽用于制备作用于免疫信号转导和/或影响肠屏障功能和/或调节代谢状态的药物 Active CN107980043B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15166598.1 2015-05-06
EP15166598 2015-05-06
PCT/EP2016/060033 WO2016177797A1 (en) 2015-05-06 2016-05-04 Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status

Publications (2)

Publication Number Publication Date
CN107980043A CN107980043A (zh) 2018-05-01
CN107980043B true CN107980043B (zh) 2021-09-24

Family

ID=74184294

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680026195.4A Active CN107980043B (zh) 2015-05-06 2016-05-04 多肽用于制备作用于免疫信号转导和/或影响肠屏障功能和/或调节代谢状态的药物

Country Status (16)

Country Link
US (2) US10738089B2 (es)
EP (1) EP3292135B1 (es)
JP (1) JP6894382B2 (es)
KR (1) KR20180011130A (es)
CN (1) CN107980043B (es)
AU (2) AU2016257315A1 (es)
BR (1) BR112017023751A2 (es)
CA (1) CA2984985A1 (es)
DK (1) DK3292135T3 (es)
EA (1) EA201700507A1 (es)
ES (1) ES2934138T3 (es)
HK (1) HK1252412A1 (es)
IL (1) IL255405B (es)
MX (1) MX2017014111A (es)
PL (1) PL3292135T3 (es)
WO (1) WO2016177797A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2551642B (en) 2014-10-31 2020-09-23 Pendulum Therapeutics Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
US10738089B2 (en) 2015-05-06 2020-08-11 Wageningen Universiteit Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
KR102581908B1 (ko) * 2015-09-10 2023-09-22 위니베르시트카솔리끄드루뱅 대사장애를 치료하기 위한 저온살균된 아커만시아의 용도
US11931400B2 (en) 2017-03-07 2024-03-19 Psomagen, Inc. Therapeutic and diagnostics compositions targeting toll-like receptors and methods thereof
WO2019018410A1 (en) * 2017-07-17 2019-01-24 The General Hospital Corporation COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
KR102340392B1 (ko) * 2018-10-08 2021-12-17 한국생명공학연구원 우울증의 예방 또는 치료 효과를 가지는 장내 미생물 및 이의 용도
KR102197180B1 (ko) * 2018-10-11 2020-12-31 주식회사 고바이오랩 아커만시아 뮤시니필라 균주 및 이를 포함하는 식욕 억제 및 대사성 질환 예방, 개선, 완화 및 치료용 조성물
CN110079474B (zh) * 2019-04-12 2022-11-25 沈阳药科大学 一种高密度培养艾克曼嗜黏蛋白菌的方法
KR102263030B1 (ko) * 2019-05-07 2021-06-10 한국생명공학연구원 염증성 장질환의 예방 또는 치료용 펩타이드
CN110227085A (zh) * 2019-07-16 2019-09-13 江苏省中医院 Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用
KR102397916B1 (ko) * 2019-10-01 2022-05-17 (주)헬스바이옴 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법
CN110950937B (zh) * 2019-11-25 2021-05-04 安徽大学 一种改造的艾克曼菌Amuc_1100蛋白及其制备方法和应用
WO2021139766A1 (en) * 2020-01-10 2021-07-15 Huang Chih Hung Peptide interacting with toll-like receptor 2 and the composition comprising the same
CN115666627A (zh) * 2020-03-25 2023-01-31 韩国生命工学研究院 源自嗜黏蛋白阿克曼菌的tars或其片段，及其用途
US20210322492A1 (en) * 2020-04-16 2021-10-21 Amucin Oy Ltd Probiotic strains and uses thereof
CN111690044B (zh) * 2020-05-06 2022-03-01 中南大学湘雅二医院 Amuc1100蛋白的用途
CN115996943A (zh) 2020-07-01 2023-04-21 瓦赫宁根大学 用于影响免疫信号传导和/或影响肠屏障功能和/或调节代谢状态的Amuc-1100多肽变体
WO2022098051A1 (ko) * 2020-11-05 2022-05-12 한국생명공학연구원 항염 및 조직 재생작용을 갖는 신규 펩타이드
CN113413466B (zh) * 2020-12-15 2022-08-19 和度生物医药(上海)有限公司 用于治疗癌症的amuc_1100和免疫检查点调节剂的组合疗法
CN117304264B (zh) * 2023-11-27 2024-02-06 中国科学院烟台海岸带研究所 一种具有肠屏障保护功能的五肽rp5及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011137369A1 (en) * 2010-04-29 2011-11-03 The Regents Of The University Of California Production of gamma-aminobutyric acid by recombinant microorganisms

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
NL1014380C2 (nl) 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.
JP3932358B2 (ja) * 2001-02-28 2007-06-20 独立行政法人産業技術総合研究所 ブラディオン遺伝子導入ショウジョウバエ株
AU2003296330A1 (en) * 2002-12-10 2004-06-30 Epimmune Inc. Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
AU2003303894A1 (en) 2003-01-30 2004-08-30 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof
US20050163764A1 (en) * 2003-09-22 2005-07-28 Yale University Treatment with agonists of toll-like receptors
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
JP5290177B2 (ja) 2006-08-31 2013-09-18 セントカー・インコーポレーテツド Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
FR2944524B1 (fr) 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
MX338680B (es) 2009-05-11 2016-04-27 Nestec Sa Bifidobacterium longum ncc2705 (cncm i-2618) y padecimientos inmunes.
US9104670B2 (en) 2010-07-21 2015-08-11 Apple Inc. Customized search or acquisition of digital media assets
CN103154670B (zh) 2010-10-20 2016-02-24 皇家飞利浦电子股份有限公司 用于识别电气网络中的耗电器的分解装置和分解方法
EP2449887B1 (en) 2010-11-05 2016-01-06 Nestec S.A. Method for preparing pet food containing probiotic micro-organisms
EP2449891A1 (en) 2010-11-05 2012-05-09 Nestec S.A. Drinking yoghurt preparations containing non-replicating probiotic micro-organisms
EP2836224A4 (en) 2012-02-29 2015-12-16 Ethicon Endo Surgery Inc COMPOSITIONS OF BIOZOOSE AND RELATED METHODS
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
KR101740893B1 (ko) * 2014-05-20 2017-06-13 주식회사 엠디헬스케어 Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
US10738089B2 (en) 2015-05-06 2020-08-11 Wageningen Universiteit Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
KR102581908B1 (ko) 2015-09-10 2023-09-22 위니베르시트카솔리끄드루뱅 대사장애를 치료하기 위한 저온살균된 아커만시아의 용도
US11071626B2 (en) 2018-03-16 2021-07-27 W. L. Gore & Associates, Inc. Diametric expansion features for prosthetic valves

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011137369A1 (en) * 2010-04-29 2011-11-03 The Regents Of The University Of California Production of gamma-aminobutyric acid by recombinant microorganisms

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity;Amandine Everard等;《PNAS》;20130528;第110卷(第22期);第9066-9071页 *
Diabetes, obesity and gut microbiota;Amandine Everard, M.Sc.;《Best Practice & Research Clinical Gastroenterology》;20130201;第27卷(第1期);第73-83页 *
EMBL Accession:B2UR41;EMBL;《EMBL UniProtKB》;20080701;第1-4页 *
Pili-like proteins of Akkermansia muciniphila modulate host immune responses and gut barrier function;Noora Ottman等;《PLoS ONE》;20170301;第12卷(第3期);第e0173004页 *
The Genome of Akkermansia muciniphila, a Dedicated Intestinal Mucin Degrader, and Its Use in Exploring Intestinal Metagenomes;Mark W. J. van Passel等;《POLS ONE》;20110303;第6卷(第3期);第e16876页 *

Also Published As

Publication number Publication date
WO2016177797A1 (en) 2016-11-10
DK3292135T3 (da) 2022-10-31
AU2020267210A1 (en) 2020-12-17
EA201700507A1 (ru) 2018-05-31
ES2934138T3 (es) 2023-02-17
CA2984985A1 (en) 2016-11-10
HK1252412A1 (zh) 2019-05-24
IL255405A0 (en) 2017-12-31
US20210147489A1 (en) 2021-05-20
AU2020267210B2 (en) 2023-10-12
CN107980043A (zh) 2018-05-01
KR20180011130A (ko) 2018-01-31
JP6894382B2 (ja) 2021-06-30
MX2017014111A (es) 2018-02-26
US20180265554A1 (en) 2018-09-20
BR112017023751A2 (pt) 2018-07-31
US10738089B2 (en) 2020-08-11
EP3292135B1 (en) 2022-09-21
PL3292135T3 (pl) 2023-01-02
JP2018515502A (ja) 2018-06-14
AU2016257315A1 (en) 2017-11-23
IL255405B (en) 2022-01-01
US11466057B2 (en) 2022-10-11
EP3292135A1 (en) 2018-03-14

Similar Documents

Publication Publication Date Title
CN107980043B (zh) 多肽用于制备作用于免疫信号转导和/或影响肠屏障功能和/或调节代谢状态的药物
JP2018515502A5 (es)
JP5871911B2 (ja) 治療用ペプチドの送達のための組成物および方法
JP2022502067A (ja) アッカーマンシアムシニフィラ菌株およびその用途
KR102028771B1 (ko) 변형된 그람 양성 박테리아 및 그 사용 방법
AU2010321674A1 (en) Recombinant microorganisms
Zhang et al. Surface-displayed Amuc_1100 from Akkermansia muciniphila on Lactococcus lactis ZHY1 improves hepatic steatosis and intestinal health in high-fat-fed zebrafish
US20230265131A1 (en) Amuc-1100 polypeptide variants for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
CN102181437B (zh) 猪脂联素球状结构域蛋白gAd基因及其编码的蛋白和应用
JP6629955B2 (ja) 減量脂質低下のための形質転換体およびその構築方法、並びにその応用
EA040421B1 (ru) Композиция, клетки, способы получения полипептида, применение полипептида и клеток, способ лечения
CN109679964A (zh) 一种表达人胰岛素基因的重组乳酸乳球菌
WO2023093883A1 (zh) 一种经遗传修饰的微生物及其应用
WO2019036859A1 (zh) 分泌glp-1及其衍生物的蛋白表达系统及其制备方法和用途
Vivekanandan et al. Overview of cloning in lactic acid bacteria: Expression and its application of probiotic potential in inflammatory bowel diseases
WO2021242897A1 (en) Recombinant bacteria for production of indole-3-acetic acid (iaa) and uses thereof
WO2021041855A1 (en) Lactococcal expression of il-35 for treatment of disease
KR20140067711A (ko) M 세포 특이 표적 펩타이드 cks9 서열이 도입되어 t세포 성장인자 단백질을 분비하는 신규한 형질전환 유산균 및 그의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant